Scientists have discovered that camel tears contain antibodies capable of neutralizing venom from at least 26 different snake species. The discovery offers a beacon of hope to millions of people across regions where snakebites are a persistent public health crisis.
The research was led by a team of veterinary and medical scientists from India’s National Research Centre on Camel (NRCC) in Bikaner and the Central Veterinary Research Laboratory (CVRL) in Dubai, who had been studying camelid immune systems for their remarkable resilience and resistance to diseases. In their work, they found that camel tears—an often-overlooked biological fluid—carry specialized antibodies known as “nanobodies,” which are small, heat-stable, and highly effective in neutralizing a wide range of toxins.
According to the scientists, these antibodies were produced after camels were safely immunized with small, non-lethal doses of snake venom. Unlike traditional antivenoms derived from horses, camel nanobodies are more stable at high temperatures and easier to store, making them ideal for use in tropical and remote settings where refrigeration is a challenge.
“This could be a game-changer,” said one of the lead researchers. “Just a single drop of these antibodies from camel tears has shown the potential to neutralize some of the world’s deadliest snake venoms in lab conditions.”
The implications are enormous. Snakebite envenomation is a major public health problem in Asia, sub-Saharan Africa, and parts of Latin America, causing more than 100,000 deaths and hundreds of thousands of disabilities each year. Many of the affected regions lack access to effective, affordable antivenoms.
Beyond the science, this discovery is also creating economic opportunities. In regions where camels are domesticated, herders are being engaged to assist in the collection of tears and blood for further research and antibody extraction, receiving fair compensation while contributing to a potentially life-saving medical advancement.
While the findings are still in the early stages and further testing—including human clinical trials—is required, medical experts and pharmaceutical companies are optimistic. Plans are already underway to explore large-scale production of camel-derived antivenoms, which could be cheaper, more effective, and safer than many existing alternatives.
If successful, this innovation may not only save lives but also shine a new light on the untapped medicinal potential of an animal long respected for its endurance and survival in harsh environments.
